claudia_zurich said:

6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized.

claudia_zurich said:

...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

andrew_nyc said:

Lp(a) and cardiovascular risk: a nuance that matters.

Bookmarking. The distinction being drawn above is the one nobody else makes. I will report back once I have actually tried it.

claudia_zurich said:

6 month update on cardiovascular risk: down 60 lbs, off blood pressure meds, A1C normalized.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

MikeNYC_runner said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here.